MedTrace Logo

Ribociclib and Letrozole Treatment in Ovarian Cancer

NCT03673124 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2025-12-23

Study results available
· View outcomes & findings →

Summary

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.

Conditions

  • Low Grade Serous Carcinoma

Interventions

DRUG

Ribociclib

600 mg by mouth daily for 21 days followed by 7 days off treatment

DRUG

Letrozole

2.5 mg by mouth daily

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Brian Slomovitz, MD · GOG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-20
Primary Completion
2024-12-23
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03673124 on ClinicalTrials.gov